Bisphosphonates in breast cancer.
Identifieur interne : 000604 ( Main/Exploration ); précédent : 000603; suivant : 000605Bisphosphonates in breast cancer.
Auteurs : Aju Mathew [États-Unis] ; Adam Brufsky [États-Unis]Source :
- International journal of cancer [ 1097-0215 ] ; 2015.
Descripteurs français
- KwdFr :
- Diphosphonates (administration et posologie), Femelle, Humains, Inhibiteurs de l'aromatase (administration et posologie), Résorption osseuse (anatomopathologie), Résorption osseuse (traitement médicamenteux), Tumeurs du sein (traitement médicamenteux), Tumeurs osseuses (anatomopathologie), Tumeurs osseuses (secondaire), Tumeurs osseuses (traitement médicamenteux).
- MESH :
- administration et posologie : Diphosphonates, Inhibiteurs de l'aromatase.
- anatomopathologie : Résorption osseuse, Tumeurs osseuses.
- secondaire : Tumeurs osseuses.
- traitement médicamenteux : Résorption osseuse, Tumeurs du sein, Tumeurs osseuses.
- Femelle, Humains.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Aromatase Inhibitors, Diphosphonates.
- drug therapy : Bone Neoplasms, Bone Resorption, Breast Neoplasms.
- pathology : Bone Neoplasms, Bone Resorption.
- secondary : Bone Neoplasms.
- Female, Humans.
Abstract
Bisphosphonates are osteoclast inhibitors, currently being used in oncology to prevent or delay bone morbidity in cancer. Oral and intravenous formulations of bisphosphonates have been found to be efficacious in preventing skeletal-related events such as bone pain, pathologic fractures, spinal cord compression and hypercalcemia of malignancy, in patients with bone metastatic breast cancer. Bisphosphonates are also used to prevent bone loss associated with anti-estrogen therapy using aromatase inhibitors. In addition to its role in preventing bone resorption, several pre-clinical studies have noted an anti-tumor role as well. Recent research effort has particularly focused on investigating an adjuvant role for bisphosphonates in early breast cancer. Recently, few randomized trials have found a beneficial effect for adjuvant use of the aminobisphosphonate, zoledronate, in older patients who are post-menopausal. This review article will summarize the various clinical studies investigating the role of bisphosphonates in breast cancer.
DOI: 10.1002/ijc.28965
PubMed: 24824552
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000179
- to stream PubMed, to step Curation: 000179
- to stream PubMed, to step Checkpoint: 000179
- to stream Ncbi, to step Merge: 002003
- to stream Ncbi, to step Curation: 002003
- to stream Ncbi, to step Checkpoint: 002003
- to stream Main, to step Merge: 000604
- to stream Main, to step Curation: 000604
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bisphosphonates in breast cancer.</title><author><name sortKey="Mathew, Aju" sort="Mathew, Aju" uniqKey="Mathew A" first="Aju" last="Mathew">Aju Mathew</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 5150 Center Avenue, UPMC Cancer Pavilion, Room 463, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 5150 Center Avenue, UPMC Cancer Pavilion, Room 463, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Brufsky, Adam" sort="Brufsky, Adam" uniqKey="Brufsky A" first="Adam" last="Brufsky">Adam Brufsky</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 300 Halket Street, Room 3524, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 300 Halket Street, Room 3524, Pittsburgh</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:24824552</idno><idno type="pmid">24824552</idno><idno type="doi">10.1002/ijc.28965</idno><idno type="wicri:Area/PubMed/Corpus">000179</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000179</idno><idno type="wicri:Area/PubMed/Curation">000179</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000179</idno><idno type="wicri:Area/PubMed/Checkpoint">000179</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000179</idno><idno type="wicri:Area/Ncbi/Merge">002003</idno><idno type="wicri:Area/Ncbi/Curation">002003</idno><idno type="wicri:Area/Ncbi/Checkpoint">002003</idno><idno type="wicri:Area/Main/Merge">000604</idno><idno type="wicri:Area/Main/Curation">000604</idno><idno type="wicri:Area/Main/Exploration">000604</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bisphosphonates in breast cancer.</title><author><name sortKey="Mathew, Aju" sort="Mathew, Aju" uniqKey="Mathew A" first="Aju" last="Mathew">Aju Mathew</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 5150 Center Avenue, UPMC Cancer Pavilion, Room 463, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 5150 Center Avenue, UPMC Cancer Pavilion, Room 463, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Brufsky, Adam" sort="Brufsky, Adam" uniqKey="Brufsky A" first="Adam" last="Brufsky">Adam Brufsky</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 300 Halket Street, Room 3524, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Hematology and Oncology, University of Pittsburgh Cancer Institute, 300 Halket Street, Room 3524, Pittsburgh</wicri:cityArea></affiliation></author></analytic><series><title level="j">International journal of cancer</title><idno type="eISSN">1097-0215</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aromatase Inhibitors (administration & dosage)</term><term>Bone Neoplasms (drug therapy)</term><term>Bone Neoplasms (pathology)</term><term>Bone Neoplasms (secondary)</term><term>Bone Resorption (drug therapy)</term><term>Bone Resorption (pathology)</term><term>Breast Neoplasms (drug therapy)</term><term>Diphosphonates (administration & dosage)</term><term>Female</term><term>Humans</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Diphosphonates (administration et posologie)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de l'aromatase (administration et posologie)</term><term>Résorption osseuse (anatomopathologie)</term><term>Résorption osseuse (traitement médicamenteux)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Tumeurs osseuses (anatomopathologie)</term><term>Tumeurs osseuses (secondaire)</term><term>Tumeurs osseuses (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Aromatase Inhibitors</term><term>Diphosphonates</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diphosphonates</term><term>Inhibiteurs de l'aromatase</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Résorption osseuse</term><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term><term>Bone Resorption</term><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Bone Neoplasms</term><term>Bone Resorption</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Résorption osseuse</term><term>Tumeurs du sein</term><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bisphosphonates are osteoclast inhibitors, currently being used in oncology to prevent or delay bone morbidity in cancer. Oral and intravenous formulations of bisphosphonates have been found to be efficacious in preventing skeletal-related events such as bone pain, pathologic fractures, spinal cord compression and hypercalcemia of malignancy, in patients with bone metastatic breast cancer. Bisphosphonates are also used to prevent bone loss associated with anti-estrogen therapy using aromatase inhibitors. In addition to its role in preventing bone resorption, several pre-clinical studies have noted an anti-tumor role as well. Recent research effort has particularly focused on investigating an adjuvant role for bisphosphonates in early breast cancer. Recently, few randomized trials have found a beneficial effect for adjuvant use of the aminobisphosphonate, zoledronate, in older patients who are post-menopausal. This review article will summarize the various clinical studies investigating the role of bisphosphonates in breast cancer.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Mathew, Aju" sort="Mathew, Aju" uniqKey="Mathew A" first="Aju" last="Mathew">Aju Mathew</name></region><name sortKey="Brufsky, Adam" sort="Brufsky, Adam" uniqKey="Brufsky A" first="Adam" last="Brufsky">Adam Brufsky</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000604 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000604 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24824552
|texte= Bisphosphonates in breast cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24824552" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |